Sanofi-Aventis Canada v. Apotex Inc., 2009 FC 676 (Ramipril*)
Justice Snider - 2009-06-29
Read full decision. Automatically generated summary:
Sanofi-Aventis Canada (Sanofi Canada) sells a drug in Canada with the trademark of ALTACE, which is used primarily in the treatment of high blood pressure and cardiac insufficiency. The active ingredient in ALTACE is ramipril. With some exceptions, Sanofi Canada purchases ramipril from its affiliate, Sanofi-Aventis Deutschland GmbH (Sanofi Deutschland) who manufactures ramipril in Germany. Ramipril is included in Canadian Patent No. 1,341,206 (the '206 Patent), a patent that was issued March 20, 2001 and held by Schering Corporation (Schering). Each of Sanofi Canada and Sanofi Deutschland are licensees under the '206 Patent.
Decision relates to:
- T-1161-07 - SANOFI-AVENTIS CANADA INC. ET AL v. NOVOPHARM LIMITED
- T-161-07 - SANOFI-AVENTIS CANADA INC. AND SCHERING CORP. v. APOTEX INC.
- A-386-09(2011 FCA 300) - which is an appeal from this decision
- T-161-07 - SANOFI-AVENTIS CANADA INC. AND SCHERING CORP. v. APOTEX INC.
- A-387-09(2011 FCA 300) - which is an appeal from this decision
- T-161-07 - SANOFI-AVENTIS CANADA INC. AND SCHERING CORP. v. APOTEX INC.
- A-389-09(2011 FCA 300) - which is an appeal from this decision
- T-161-07 - SANOFI-AVENTIS CANADA INC. AND SCHERING CORP. v. APOTEX INC.
- A-390-09(2011 FCA 300) - which is an appeal from this decision